Atlas Trials

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

Clinical trial NCT06284564 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06284564
Sponsor
M.D. Anderson Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Renal Cell Carcinoma
Start date
2024-08-07
Primary completion
2026-10-01
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.